Consumer Reports Negative on Teva Pharma (TEVA), Mylan (MYL) Deal

Consumer Reports is out negative on the potential deal between Mylan (Nasdaq: MYL) and Teva Pharma (NYSE: TEVA).

In part, the report notes that the deal could hand consumers higher prices for generic and specialty drugs.

Teva and Mylan are both trading at or near session lows on Friday.

You May Also Be Interested In

• Diana Shipping withdraws bid to acquire Genco Shipping
• Paramount Skydance clears global regulators for WBD deal, faces state AG suit
• Nuclea Energy agrees to buy Moltex nuclear technology assets